Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib with subcutaneous amivantamab manual injection versus intravenous amivantamab or subcutaneous OBDS amivantamab in EGFR-mutated advanced or metastatic non-small cell lung cancer after osimertinib and chemotherapy
2022-000525-25Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Janssen Pharmaceutical. Started Jun 2022; status: active.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-000525-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000525-25.